Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0045 in Patients With Advanced Solid Tumors

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HB 0045 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Ductal carcinoma; Fallopian tube cancer; Head and neck cancer; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Prostate cancer; Renal cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Huabo Biopharm

Most Recent Events

  • 20 Jul 2023 According to a Shanghai Huahuituo Pharmaceutical Technology media release, Shanghai Huaaotai Biopharmaceutical Co., Ltd. independently developed the clinical trial application of HB0045 injection for the treatment of advanced solid tumors and was approved by the US Food and Drug Administration (FDA).
  • 20 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top